Enhancing Respiratory Syncytial Virus Immunoprophylaxis: Addressing Challenges Beyond Palivizumab in the Gulf Region.
作者信息
Babar Anas
机构信息
Department of Medicine and Surgery, King Edward Medical University, Lahore, Pakistan.
出版信息
Oman Med J. 2025 Jan 31;40(1):e726. doi: 10.5001/omj.2025.65. eCollection 2025 Jan.
Abstract
摘要
相似文献
1
Enhancing Respiratory Syncytial Virus Immunoprophylaxis: Addressing Challenges Beyond Palivizumab in the Gulf Region.加强呼吸道合胞病毒免疫预防：应对海湾地区除帕利珠单抗之外的挑战
Oman Med J. 2025 Jan 31;40(1):e726. doi: 10.5001/omj.2025.65. eCollection 2025 Jan.
2
Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region.帕利珠单抗预防呼吸道合胞病毒疾病：海湾合作委员会地区专家意见与建议
Oman Med J. 2024 Sep 30;39(5):e667. doi: 10.5001/omj.2024.111. eCollection 2024 Sep.
3
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒（RSV）毛细支气管炎的免疫预防作用：亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
4
Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.高危婴儿呼吸道合胞病毒免疫预防的经济学分析：一项系统评价
Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034-41. doi: 10.1001/archpedi.156.10.1034.
5
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.使用帕利珠单抗对儿童进行呼吸道合胞病毒（RSV）免疫预防：一项系统评价与经济学评估
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. doi: 10.3310/hta12360.
6
Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.巴西北部帕拉州接受帕利珠单抗免疫预防的先天性心脏病患儿呼吸道合胞病毒感染发生率。
BMC Pediatr. 2019 Aug 28;19(1):299. doi: 10.1186/s12887-019-1681-6.
7
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
8
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2014 May 22(5):CD007743. doi: 10.1002/14651858.CD007743.pub5.
9
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2016 Jul 20;7(7):CD007743. doi: 10.1002/14651858.CD007743.pub6.
10
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2013 Jun 5(6):CD007743. doi: 10.1002/14651858.CD007743.pub4.
本文引用的文献
1
Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region.帕利珠单抗预防呼吸道合胞病毒疾病：海湾合作委员会地区专家意见与建议
Oman Med J. 2024 Sep 30;39(5):e667. doi: 10.5001/omj.2024.111. eCollection 2024 Sep.
2
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.国际风险评分工具的使用对加拿大中晚期早产儿使用帕利珠单抗预防严重呼吸道合胞病毒感染的成本-效用的影响。
J Med Econ. 2023 Jan-Dec;26(1):630-643. doi: 10.1080/13696998.2023.2202600.
3
Variations in respiratory syncytial virus activity following the relaxation of COVID-19 restrictions in Qatar.卡塔尔放松新冠疫情限制措施后呼吸道合胞病毒活动的变化
J Travel Med. 2022 Sep 17;29(6). doi: 10.1093/jtm/taac065.
Zotero 插件